Lefamulin. Comment on: “Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. <i>Microorganisms</i>, 2019, <i>7</i>, 270”
On 18 August 2019, an article was published in <i>Microorganisms</i> presenting novel, approved anti-Gram-positive antibiotics. On 19 August 2019, the U.S. Food and Drug Administration announced the approval of lefamulin, a representative of a new class of antibiotics, the pleuromutilins...
Main Authors: | Despoina Koulenti, Elena Xu, Isaac Yin Sum Mok, Andrew Song, Drosos E. Karageorgopoulos, Apostolos Armaganidis, Jeffrey Lipman, Sotirios Tsiodras |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-09-01
|
Series: | Microorganisms |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-2607/7/10/386 |
Similar Items
-
Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities
by: Thomas M. File, et al.
Published: (2021-05-01) -
Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms
by: Despoina Koulenti, et al.
Published: (2019-08-01) -
Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms
by: Despoina Koulenti, et al.
Published: (2020-01-01) -
In vitro Activity of Lefamulin Against the Common Respiratory Pathogens Isolated From Mainland China During 2017–2019
by: Shi Wu, et al.
Published: (2020-09-01) -
The Continuing Threat of Methicillin-Resistant <i>Staphylococcus aureus</i>
by: Márió Gajdács
Published: (2019-05-01)